Argus Downgrades Celgene (CELG) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
UPDATE: Bernstein Upgrades Celgene (CELG) to Outperform
May 23, 2018 6:32 AM EDT(Updated - May 23, 2018 8:09 AM EDT)
(updated to expand anlayst comment)
Bernstein upgraded Celgene (NASDAQ: CELG) from Market Perform to Outperform, price target $102.00 (from $121.00).
Analyst Arron Gal believes the worst case scenario relative to a generic Revlimid entry in April... More
